Terms: = Lymphoma AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
3269 results:
1. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. [Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell lymphoma Cells].
Zhang YL; Chen YH; Zheng RJ; Zheng KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):470-475. PubMed ID: 38660854
[TBL] [Abstract] [Full Text] [Related]
3. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
[TBL] [Abstract] [Full Text] [Related]
4. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
5. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
[TBL] [Abstract] [Full Text] [Related]
6. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract] [Full Text] [Related]
7. Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
Song Y; Li J; Zhou K; Ke X; Cai Z; Zhang H; Yao T; Xia Z; Wang Y; Lai P; Liu X; Zhu J
Leuk Lymphoma; 2024 May; 65(5):647-652. PubMed ID: 38557285
[TBL] [Abstract] [Full Text] [Related]
8. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.
Hoang NM; Liu Y; Bates PD; Heaton AR; Lopez AF; Liu P; Zhu F; Chen R; Kondapelli A; Zhang X; Selberg PE; Ngo VN; Skala MC; Capitini CM; Rui L
Cell Rep Med; 2024 Apr; 5(4):101484. PubMed ID: 38554704
[TBL] [Abstract] [Full Text] [Related]
9. BCL-2 inhibition in haematological malignancies: Clinical application and complications.
Fowler-Shorten DJ; Hellmich C; Markham M; Bowles KM; Rushworth SA
Blood Rev; 2024 May; 65():101195. PubMed ID: 38523032
[TBL] [Abstract] [Full Text] [Related]
10. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Wolska-Washer A; Robak P; Witkowska M; Robak T
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
[TBL] [Abstract] [Full Text] [Related]
11. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract] [Full Text] [Related]
12. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
13. The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma.
Zhang T; Wang ZT; Li Z; Yin SX; Wang X; Chen HZ
J Cancer Res Clin Oncol; 2024 Mar; 150(3):120. PubMed ID: 38466431
[TBL] [Abstract] [Full Text] [Related]
14. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell lymphoma.
Lymphoma Research Foundation LRF
Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
[TBL] [Abstract] [Full Text] [Related]
15. [Effect of Chlorambucil Combined with Ibrutinib on Mantle Cell lymphoma Cell Line Jeko-1 and Its Related Mechanism].
Cai NN; Liu WY; Liu ZQ; Gong JH; Lin YL; Wang ZC; Huang YQ; Guo JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):132-137. PubMed ID: 38387911
[TBL] [Abstract] [Full Text] [Related]
16. [Efficacy and Prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell lymphoma].
Chen H; Liu XY; Chang Y; Chen ZQ; Li WQ; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):125-131. PubMed ID: 38387910
[TBL] [Abstract] [Full Text] [Related]
17. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the lymphoma and Related Diseases Registry.
Baggio D; Wellard C; Chung E; Talaulikar D; Keane C; Opat S; Giri P; Minson A; Cheah CY; Armytage T; Lee D; Chong G; Johnston A; Cochrane T; Waters N; Hamad N; Wood EM; Hawkes EA
Leuk Lymphoma; 2023 Mar; 64(3):621-627. PubMed ID: 38376128
[TBL] [Abstract] [Full Text] [Related]
18. Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
Liu H; Zou H; Shan D; Liu W; Huang W; Sui W; Deng S; Wang T; Lv R; Fu M; Xu Y; Yi S; An G; Zhao Y; Qiu L; Zou D
Cancer Med; 2024 Jan; 13(2):e6965. PubMed ID: 38348996
[TBL] [Abstract] [Full Text] [Related]
19. Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma.
Quesada AE; Hu S; Li S; Toruner GA; Wei Q; Loghavi S; Ok CY; Jain P; Thakral B; Nwogbo OV; Kim D; Iyer SP; You MJ; Medeiros LJ; Tang G
Hum Pathol; 2024 Feb; 144():71-76. PubMed ID: 38301962
[TBL] [Abstract] [Full Text] [Related]
20. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract] [Full Text] [Related]
[Next]
